Psoriasis is a common cutaneous disease that can have a profound effect on an individual's life. New biologic drugs--proteins that are synthesized using recombinant DNA technology to mimic naturally occurring molecules and that selectively target the immune system--have changed the paradigm for treating this disease. We review 4 biologic drugs that are either currently FDA approved or in phase 3 studies: Alefacept (Amevive) and efalizumab (Raptiva), which are T-cell modulators; etanercept (Enbrel), a soluble TNF receptor; and infliximab (Remicade), an anti-TNF monoclonal antibody.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
biologic therapies
4
therapies psoriatic
4
psoriatic disease
4
disease psoriasis
4
psoriasis common
4
common cutaneous
4
cutaneous disease
4
disease profound
4
profound individual's
4
individual's life
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!